Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
P/E ratio for Kinnate Biopharma Inc. (KNTE)
P/E ratio as of 2023: -0.98
According to Kinnate Biopharma Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.98. At the end of 2022 the company had a P/E ratio of -2.36.
P/E ratio history for Kinnate Biopharma Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.98 |
| 2022 | -2.36 |
| 2021 | -8.64 |
| 2020 | -48.81 |
| 2019 | -141.80 |
| 2018 | -55.25 |